Understanding metabolic dependencies and their therapeutic vulnerabilities is key to precision oncology. Malic enzyme 1 (ME1) is frequently overexpressed in cancers with protumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer.
CITATION STYLE
Subbiah, V., & Gan, B. (2022). Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All about ME1? Clinical Cancer Research, 28(16), 3408–3410. https://doi.org/10.1158/1078-0432.CCR-22-1257
Mendeley helps you to discover research relevant for your work.